Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 1/2019

01-02-2019 | Atenolol | Review Article

Comparative efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm: systematic review and meta-analysis

Authors: Nashmil Ghadimi, Sara Kaveh, Hossein Shabaninejad, Alaadine Lijassi, Ali Zahed Mehr, Hossein Hosseinifard

Published in: International Journal of Clinical Pharmacy | Issue 1/2019

Login to get access

Abstract

Background Patients with mitral valve stenosis have increased heart rate. HR reduction is known as an important treatment and therapy strategy for patients with mitral valve stenosis. Aim of the review The aim of this systematic review and meta-analysis was to compare the efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm. Methods Randomized controlled trials were searched in Cochrane Library, PubMed, Web of Science, CRD, Scopus, and Google Scholar with no start time limitation and ending June 2018. Risk of bias across was assessed by the Cochrane Risk of Bias Assessment tool. Fixed effects models were used to combine the results and the mean difference with a 95% confidence interval. This meta-analysis was performed using Meta Package in R software. Results Five studies entered meta-analysis. The total number of patients treated with ivabradine and beta-blockers was 178 and 178 respectively. The results showed that the mean of maximum HR and HR at rest was lower at about 5.03 units and upper 4.32 units respectively with use of ivabradine compared with the use of beta-blockers. These values were statistically significant. Conclusion It seems that the efficacy of ivabradine is good in comparison with betablockers, but it still requires more clinical trials.
Appendix
Available only for authorised users
Literature
1.
go back to reference De Santis V, Vitale D, Santoro A, Magliocca A, Porto AG, Nencini C, et al. Ivabradine: potential clinical applications in critically ill patients. Clin Res Cardiol. 2013;102(3):171–8.CrossRef De Santis V, Vitale D, Santoro A, Magliocca A, Porto AG, Nencini C, et al. Ivabradine: potential clinical applications in critically ill patients. Clin Res Cardiol. 2013;102(3):171–8.CrossRef
2.
go back to reference Guglin M. Heart rate reduction in heart failure: ivabradine or beta blockers? Heart Fail Rev. 2013;18(4):517–28.CrossRef Guglin M. Heart rate reduction in heart failure: ivabradine or beta blockers? Heart Fail Rev. 2013;18(4):517–28.CrossRef
3.
go back to reference Al Zaibag M, Al Kasab S, Ribeiro P, Al Fagih M. Percutaneous double-balloon mitral valvotomy for rheumatic mitral-valve stenosis. Lancet. 1986;327(8484):757–61.CrossRef Al Zaibag M, Al Kasab S, Ribeiro P, Al Fagih M. Percutaneous double-balloon mitral valvotomy for rheumatic mitral-valve stenosis. Lancet. 1986;327(8484):757–61.CrossRef
4.
go back to reference Carabello BA. Mitral valve regurgitation. Curr Probl Cardiol. 1998;23(4):197–241.CrossRef Carabello BA. Mitral valve regurgitation. Curr Probl Cardiol. 1998;23(4):197–241.CrossRef
5.
go back to reference Sun JP, Felner JM. Mitral Valve Stenosis. Practical Handbook of Echocardiography: 101 Case Studies. 2010:38-41. Sun JP, Felner JM. Mitral Valve Stenosis. Practical Handbook of Echocardiography: 101 Case Studies. 2010:38-41.
6.
go back to reference Muhammad F, Nazeer A, Rehman Z. The comparison of effects of ivabradine and atenolol on heart rate and symptoms in patients with mild-to-moderate mitral stenosis. Pak J Med Health Sci. 2016;10(2):345–7. Muhammad F, Nazeer A, Rehman Z. The comparison of effects of ivabradine and atenolol on heart rate and symptoms in patients with mild-to-moderate mitral stenosis. Pak J Med Health Sci. 2016;10(2):345–7.
7.
go back to reference Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr., Faxon DP, Freed MD, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2006;48(3):e1–148.CrossRef Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr., Faxon DP, Freed MD, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2006;48(3):e1–148.CrossRef
8.
go back to reference Guglin M. Heart rate reduction in heart failure: ivabradine or beta blockers? Heart Fail Rev. 2013;18(4):517–28.CrossRef Guglin M. Heart rate reduction in heart failure: ivabradine or beta blockers? Heart Fail Rev. 2013;18(4):517–28.CrossRef
9.
go back to reference Members TF, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003.CrossRef Members TF, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003.CrossRef
10.
go back to reference Riccioni G. Ivabradine: the hope for a good treatment of ischemic heart disease. Curr Med Chem. 2013;20(14):1817–23.CrossRef Riccioni G. Ivabradine: the hope for a good treatment of ischemic heart disease. Curr Med Chem. 2013;20(14):1817–23.CrossRef
11.
go back to reference Alan S, Ulgen MS, Ozdemir K, Keles T, Toprak N. Reliability and efficacy of metoprolol and diltiazem in patients having mild to moderate mitral stenosis with sinus rhythm. Angiology. 2002;53(5):575–81.CrossRef Alan S, Ulgen MS, Ozdemir K, Keles T, Toprak N. Reliability and efficacy of metoprolol and diltiazem in patients having mild to moderate mitral stenosis with sinus rhythm. Angiology. 2002;53(5):575–81.CrossRef
12.
go back to reference Monmeneu JM, Marín FO, Reyes FG, Jordán AT, García MM, Bodí VP, et al. Beta-blockade and exercise capacity in patients with mitral stenosis in sinus rhythm. J Heart Valve Dis. 2002;11(2):199–203. Monmeneu JM, Marín FO, Reyes FG, Jordán AT, García MM, Bodí VP, et al. Beta-blockade and exercise capacity in patients with mitral stenosis in sinus rhythm. J Heart Valve Dis. 2002;11(2):199–203.
13.
go back to reference Tardif J-C, Ponikowski P, Kahan T. Efficacy of the I f current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30(5):540–8.CrossRef Tardif J-C, Ponikowski P, Kahan T. Efficacy of the I f current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30(5):540–8.CrossRef
14.
go back to reference DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res. 2006;53(5):399–406.CrossRef DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res. 2006;53(5):399–406.CrossRef
15.
go back to reference De Santis V, Vitale D, Santoro A, Magliocca A, Porto AG, Nencini C, et al. Ivabradine: potential clinical applications in critically ill patients. Clin Res Cardiol. 2013;102(3):171–8.CrossRef De Santis V, Vitale D, Santoro A, Magliocca A, Porto AG, Nencini C, et al. Ivabradine: potential clinical applications in critically ill patients. Clin Res Cardiol. 2013;102(3):171–8.CrossRef
16.
go back to reference Fala L. Corlanor (Ivabradine), First HCN Channel Blocker, FDA Approved for the Treatment of Patients with Heart Failure. Am Health Drug Benefits. 2016;9(Spec Feature):56.PubMedPubMedCentral Fala L. Corlanor (Ivabradine), First HCN Channel Blocker, FDA Approved for the Treatment of Patients with Heart Failure. Am Health Drug Benefits. 2016;9(Spec Feature):56.PubMedPubMedCentral
17.
go back to reference Speranza L, Franceschelli S, Riccioni G. The biological effects of ivabradine in cardiovascular disease. Molecules. 2012;17(5):4924–35.CrossRef Speranza L, Franceschelli S, Riccioni G. The biological effects of ivabradine in cardiovascular disease. Molecules. 2012;17(5):4924–35.CrossRef
18.
go back to reference Urbanek I, Kaczmarek K, Cygankiewicz I, Ptaszynski P. Risk-benefit assessment of ivabradine in the treatment of chronic heart failure. Drug Healthc Patient Saf. 2014;6:47.PubMedPubMedCentral Urbanek I, Kaczmarek K, Cygankiewicz I, Ptaszynski P. Risk-benefit assessment of ivabradine in the treatment of chronic heart failure. Drug Healthc Patient Saf. 2014;6:47.PubMedPubMedCentral
19.
go back to reference Werdan K, Perings S, Köster R, Kelm M, Meinertz T, Stöckl G, et al. Effectiveness of ivabradine treatment in different subpopulations with stable angina in clinical practice: a pooled analysis of observational studies. Cardiology. 2016;135(3):141–50.CrossRef Werdan K, Perings S, Köster R, Kelm M, Meinertz T, Stöckl G, et al. Effectiveness of ivabradine treatment in different subpopulations with stable angina in clinical practice: a pooled analysis of observational studies. Cardiology. 2016;135(3):141–50.CrossRef
20.
go back to reference Agrawal V, Kumar N, Lohiya B, Sihag BK, Prajapati R, Singh T, et al. Metoprolol vs ivabradine in patients with mitral stenosis in sinus rhythm. Int J Cardiol. 2016;221:562–6.CrossRef Agrawal V, Kumar N, Lohiya B, Sihag BK, Prajapati R, Singh T, et al. Metoprolol vs ivabradine in patients with mitral stenosis in sinus rhythm. Int J Cardiol. 2016;221:562–6.CrossRef
21.
go back to reference Muhammad F, Nazeer A, Rehman Z. The comparison of effects of ivabradine and atenolol on heart rate and symptoms in patients with mild-to-moderate mitral stenosis. Pak J Med Health Sci. 2016;10(2):345–7. Muhammad F, Nazeer A, Rehman Z. The comparison of effects of ivabradine and atenolol on heart rate and symptoms in patients with mild-to-moderate mitral stenosis. Pak J Med Health Sci. 2016;10(2):345–7.
22.
go back to reference Rajesh GN, Sajeer K, Sajeev CG, Bastian C, Vinayakumar D, Muneer K, et al. A comparative study of ivabradine and atenolol in patients with moderate mitral stenosis in sinus rhythm. Indian Heart J. 2016;68(3):311–5.CrossRef Rajesh GN, Sajeer K, Sajeev CG, Bastian C, Vinayakumar D, Muneer K, et al. A comparative study of ivabradine and atenolol in patients with moderate mitral stenosis in sinus rhythm. Indian Heart J. 2016;68(3):311–5.CrossRef
23.
go back to reference Saggu DK, Narain VS, Dwivedi SK, Sethi R, Chandra S, Puri A, et al. Effect of ivabradine on heart rate and duration of exercise in patients with mild-to-moderate mitral stenosis: a randomized comparison with metoprolol. J Cardiovasc Pharmacol. 2015;65(6):552.CrossRef Saggu DK, Narain VS, Dwivedi SK, Sethi R, Chandra S, Puri A, et al. Effect of ivabradine on heart rate and duration of exercise in patients with mild-to-moderate mitral stenosis: a randomized comparison with metoprolol. J Cardiovasc Pharmacol. 2015;65(6):552.CrossRef
24.
go back to reference Parakh N, Chaturvedi V, Kurian S, Tyagi S. Effect of ivabradine vs atenolol on heart rate and effort tolerance in patients with mild to moderate mitral stenosis and normal sinus rhythm. J Card Fail. 2012;18(4):282–8.CrossRef Parakh N, Chaturvedi V, Kurian S, Tyagi S. Effect of ivabradine vs atenolol on heart rate and effort tolerance in patients with mild to moderate mitral stenosis and normal sinus rhythm. J Card Fail. 2012;18(4):282–8.CrossRef
25.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.CrossRef Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.CrossRef
26.
go back to reference Higgins J. Green S. Cochrane handbook for systematic reviews of interventions Version 5.1. 0. The Cochrane Collaboration. Confidence intervals. 2011. Higgins J. Green S. Cochrane handbook for systematic reviews of interventions Version 5.1. 0. The Cochrane Collaboration. Confidence intervals. 2011.
27.
go back to reference Otto CM, Gaasch W, Yeon S. Clinical Manifestations and diagnosis of rheumatic mitral stenosis. UpToDate, Post, TW. 2018. Otto CM, Gaasch W, Yeon S. Clinical Manifestations and diagnosis of rheumatic mitral stenosis. UpToDate, Post, TW. 2018.
28.
go back to reference Mardikar H, Sahasrabhojaney V, Jalgaonkar P, Mahorkar U, Mardikar M, Waghmare B. Long term effects of atenolol in patients of mitral stenosis and normal sinus rhythm. Indian J Med Res. 1995;101:25–7.PubMed Mardikar H, Sahasrabhojaney V, Jalgaonkar P, Mahorkar U, Mardikar M, Waghmare B. Long term effects of atenolol in patients of mitral stenosis and normal sinus rhythm. Indian J Med Res. 1995;101:25–7.PubMed
29.
go back to reference Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine, a novel If inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100(3):149–55.CrossRef Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine, a novel If inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100(3):149–55.CrossRef
30.
go back to reference Pasceri E, Curcio A, Achille F, de Serio D, Zinzi S, Torella D. Acute reduction of transmitral gradient after I (f) channel inhibition in patients with mitral valve stenosis or a mitral annuloplasty ring [Abst 974]. Europace. 2009;11(Suppl 2):S6. Pasceri E, Curcio A, Achille F, de Serio D, Zinzi S, Torella D. Acute reduction of transmitral gradient after I (f) channel inhibition in patients with mitral valve stenosis or a mitral annuloplasty ring [Abst 974]. Europace. 2009;11(Suppl 2):S6.
31.
go back to reference Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107(6):817–23.CrossRef Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107(6):817–23.CrossRef
32.
go back to reference López-Bescós L, Filipova S, Martos R. Long-term safety and efficacy of ivabradine in patients with chronic stable angina. Cardiology. 2007;108(4):387–96.CrossRef López-Bescós L, Filipova S, Martos R. Long-term safety and efficacy of ivabradine in patients with chronic stable angina. Cardiology. 2007;108(4):387–96.CrossRef
33.
go back to reference Tardif J-C, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I f inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529–36.CrossRef Tardif J-C, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I f inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529–36.CrossRef
34.
go back to reference Ye L, Ke D, Chen Q, Li G, Deng W, Wu Z. Effectiveness of ivabradine in treating stable angina pectoris. Medicine. 2016;95(14):e3245. Ye L, Ke D, Chen Q, Li G, Deng W, Wu Z. Effectiveness of ivabradine in treating stable angina pectoris. Medicine. 2016;95(14):e3245.
Metadata
Title
Comparative efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm: systematic review and meta-analysis
Authors
Nashmil Ghadimi
Sara Kaveh
Hossein Shabaninejad
Alaadine Lijassi
Ali Zahed Mehr
Hossein Hosseinifard
Publication date
01-02-2019
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 1/2019
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-018-00778-z

Other articles of this Issue 1/2019

International Journal of Clinical Pharmacy 1/2019 Go to the issue